The risk of disease progression was also 2.6 times higher (95% CI: 1.6–4.2; p < 0.001) in patients with high B7-H3 expression, suggesting that it may serve as a potential adverse prognostic marker in glial neoplasms. This evidence concerns the gene CD276 and glioma.